XML 84 R65.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES - Contingencies Related to Stanford and Merger Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended
Mar. 31, 2023
Feb. 28, 2023
Jun. 30, 2023
Jan. 31, 2024
Nov. 15, 2021
Other Commitments          
Contingent milestone consideration paid in shares value     $ 2,354    
CHASE Phase 2b clinical trial of KPI-012          
Other Commitments          
Contingent upon specified development, regulatory and commercialization milestones     $ 175    
Combangio, Inc          
Other Commitments          
Contingent upon specified development, regulatory and commercialization milestones         $ 40,000
Combangio, Inc | First Patient Dosed With Any Product in Phase 2 Clinical Trial, Dosing Milestone          
Other Commitments          
Potential maximum payout for contingent consideration         $ 65,000
Contingent milestone consideration paid   $ 2,500      
Contingent milestone consideration paid in shares value   $ 2,354      
Contingent milestone consideration paid in shares 105,038   105,038    
Combangio, Inc | First Patient Dosed With Any Product in Phase 2 Clinical Trial, Dosing Milestone | Subsequent Events          
Other Commitments          
Contingent milestone consideration       $ 146